JPMorgan Chase & Co. raised its stake in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 1.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,044 shares of the company’s stock after buying an additional 196 shares during the period. JPMorgan Chase & Co. owned about 0.06% of USANA Health Sciences worth $924,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Teachers Advisors LLC raised its position in shares of USANA Health Sciences by 137.7% in the fourth quarter. Teachers Advisors LLC now owns 217,677 shares of the company’s stock valued at $13,322,000 after buying an additional 126,090 shares during the period. Norges Bank acquired a new position in shares of USANA Health Sciences during the fourth quarter valued at about $6,855,000. State Street Corp raised its position in shares of USANA Health Sciences by 104.3% in the fourth quarter. State Street Corp now owns 190,838 shares of the company’s stock valued at $11,676,000 after buying an additional 97,430 shares during the period. Russell Investments Group Ltd. acquired a new position in shares of USANA Health Sciences during the fourth quarter valued at about $1,535,000. Finally, Oxford Asset Management acquired a new position in shares of USANA Health Sciences during the first quarter valued at about $1,166,000. Institutional investors and hedge funds own 43.57% of the company’s stock.
USANA Health Sciences, Inc. (NYSE:USNA) traded up 1.07% during mid-day trading on Friday, hitting $56.55. 80,875 shares of the stock traded hands. The stock has a market cap of $1.38 billion, a P/E ratio of 14.69 and a beta of 1.10. The stock has a 50-day moving average price of $60.17 and a 200-day moving average price of $60.33. USANA Health Sciences, Inc. has a 12 month low of $52.55 and a 12 month high of $150.00.
USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings data on Tuesday, July 25th. The company reported $0.98 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.08. USANA Health Sciences had a return on equity of 28.93% and a net margin of 9.47%. The company had revenue of $257.10 million for the quarter, compared to analysts’ expectations of $273.61 million. During the same period in the previous year, the business posted $2.07 EPS. The business’s revenue for the quarter was down .5% on a year-over-year basis. On average, equities analysts forecast that USANA Health Sciences, Inc. will post $3.79 earnings per share for the current year.
USANA Health Sciences announced that its Board of Directors has authorized a share buyback plan on Tuesday, July 25th that permits the company to repurchase $64.60 million in outstanding shares. This repurchase authorization permits the company to repurchase up to 46% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its shares are undervalued.
ILLEGAL ACTIVITY NOTICE: “JPMorgan Chase & Co. Has $924,000 Position in USANA Health Sciences, Inc. (NYSE:USNA)” was originally posted by BNB Daily and is owned by of BNB Daily. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.baseball-news-blog.com/2017/08/19/usana-health-sciences-inc-nyseusna-position-raised-by-jpmorgan-chase-co-updated-updated-updated.html.
Several research analysts have issued reports on USNA shares. Pivotal Research restated a “hold” rating and set a $55.00 target price (down previously from $75.00) on shares of USANA Health Sciences in a research report on Monday, May 1st. BidaskClub downgraded shares of USANA Health Sciences from a “buy” rating to a “hold” rating in a research note on Tuesday, June 20th.
In other USANA Health Sciences news, major shareholder Global Ltd Gull sold 25,467 shares of the firm’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $56.52, for a total value of $1,439,394.84. Following the completion of the transaction, the insider now owns 12,352,753 shares of the company’s stock, valued at approximately $698,177,599.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Paul A. Jones sold 9,851 shares of the firm’s stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $64.50, for a total transaction of $635,389.50. Following the completion of the transaction, the insider now directly owns 6,020 shares of the company’s stock, valued at approximately $388,290. The disclosure for this sale can be found here. Insiders sold a total of 171,334 shares of company stock valued at $10,413,675 in the last three months. 53.20% of the stock is currently owned by corporate insiders.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
Receive News & Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.